Call for papers: Cell and molecular therapy for cardiovascular disorders

BMC Cardiovascular Disorders warmly welcomes submissions to a new article Collection on cell and molecular therapy for cardiovascular disorders.
 Call for papers: Cell and molecular therapy for cardiovascular disorders
Like

BMC Cardiovascular Disorders is calling for submissions to our Collection on cell and molecular therapy for cardiovascular diseases. Scientists from around the globe are investigating/leveraging cell and molecular-based strategies to protect, regenerate, replace, and restore the function of cardiac and vascular tissue. Advances in basic and clinical research have yielded encouraging findings highlighting the promise of such strategies to treat a range of CVDs. However, gaps in our knowledge remain and further research is required to translate findings from basic research into the clinic. 

In support of SDG 3: Good Health & Wellbeing, BMC Cardiovascular Disorders calls for papers exploring the potential of stem cells, gene editing, tissue engineering, disease modeling, and organoids to improve our understanding of cardiovascular diseases and open new avenues for therapeutic intervention. 

Meet the Guest Editors

Sherin Saheera: University of Massachusetts Chan Medical School, US

Dr Sherin Saheera completed her PhD in India in 2017 and went to the US to pursue her postdoctoral studies. After a year of training at the University of Alabama at Birmingham, she is currently working as a Postdoctoral Associate at the University of Massachusetts, Chan Medical School, where she has been  since January 2019. She has over 18 publications in peer reviewed high impact journals and has been serving as an editorial board member and reviewer for reputed journals. She has also presented papers in several national and international conferences.

Huiliang Zhang: University of Arkansas for Medical Sciences, US
Dr Zhang’s research focuses on cardiac dysfunction in the aging heart with an emphasis on the pathogenic role of elevated proton leak from mitochondria. He explores the strategies for restoring mitochondrial function and stem cell therapies to reverse cardiac dysfunction in preclinical models of aging. Dr. Zhang is the principal investigator of the NIH R35 grant and the American Heart Association (AHA) Career Development Award. Dr. Zhang served in NIH and AHA study sections. He has nearly 40 original publications and has won several national trainee and junior faculty awards.

Submission Guidelines

This Collection welcomes submission of original Research Articles. Should you wish to submit a different article type, please read our submission guidelines to confirm that type is accepted by the journal. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a Collection, please select "Cell and molecular therapy for cardiovascular disorders" from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.

Submission Status: Open   |   Submission Deadline: 21 June 2024

Please sign in or register for FREE

If you are a registered user on Research Communities by Springer Nature, please sign in

Subscribe to the Topic

Cardiovascular Diseases
Life Sciences > Health Sciences > Clinical Medicine > Diseases > Cardiovascular Diseases
Health Care
Life Sciences > Health Sciences > Health Care

Related Collections

With collections, you can get published faster and increase your visibility.

Cell and molecular therapy for cardiovascular disorders

BMC Cardiovascular Disorders is calling for submissions to our Collection on cell and molecular therapy for cardiovascular diseases. Scientists from around the globe are investigating/leveraging cell and molecular-based strategies to protect, regenerate, replace and restore the function of cardiac and vascular tissue. Advances in basic and clinical research have yielded encouraging findings highlighting the promise of such strategies to treat a range of CVDs. However, gaps in our knowledge remain and further research is required to translate findings from basic research into the clinic. In support of SDG 3: Good Health & Wellbeing, BMC Cardiovascular Disorders calls for papers exploring the potential of stem cells, gene editing, tissue engineering, disease modeling and organoids to improve our understanding of cardiovascular diseases and open new avenues for therapeutic intervention.

Publishing Model: Open Access

Deadline: Jun 21, 2024

Adult congenital heart disease

Adult Congenital Heart Disease (ACHD) is a growing public health concern worldwide. Millions of people are living with ACHD as more children with congenital heart disease reach adulthood. ACHD encompasses a wide range of structural and functional heart abnormalities, including blood vessel (e.g. aortic coarctation, aortic and pulmonary artery stenosis, patent ductus arteriosus, transposition of the great arteries and anomalous pulmonary venous return), heart valve (e.g. bicuspid aortic valve disease, Ebstein’s anomaly and mitral valve prolapse) and septal defects (e.g. atrial septal defect, patent foramen ovale and ventricular septal defect), that develop before birth but are not diagnosed until adulthood. In support of SDG 3, BMC Cardiovascular Disorders is launching a new Collection on Adult Congenital Heart Disease to bring together basic and clinical research to develop our understanding of ACHD and improve the care and outcomes for patients living with this condition. We welcome submissions on topics such as: • Advances in diagnosis and imaging • Long-term outcomes and quality of life • Management of arrhythmias and heart failure • Innovative treatments and surgical techniques Living with ACHD can present significant challenges for patients, including the need for lifelong monitoring, multiple surgeries, and a higher risk of heart failure as well as other cardiovascular complications. We hope this Collection can serve as a platform for researchers to showcase the latest advances in the epidemiology, pathophysiology, diagnosis, and treatment of ACHD.

Publishing Model: Open Access

Deadline: Apr 24, 2024